Get the Stockscreener App
11.18
1.24%
-0.14
After Hours:
11.18
Ars Pharmaceuticals Inc stock is traded at $11.18, with a volume of 2.56M.
It is down -1.24% in the last 24 hours and down -17.49% over the past month.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
See More
Previous Close:
$11.32
Open:
$11.18
24h Volume:
2.56M
Relative Volume:
2.34
Market Cap:
$1.09B
Revenue:
-
Net Income/Loss:
$-44.84M
P/E Ratio:
-23.01
EPS:
-0.4858
Net Cash Flow:
$-44.23M
1W Performance:
-6.05%
1M Performance:
-17.49%
6M Performance:
+44.63%
1Y Performance:
+121.83%
1-Day Range:
$10.83
$11.56
1-Week Range:
$10.63
$12.39
52-Week Range:
$5.02
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Name
Ars Pharmaceuticals Inc
Sector
Industry
Phone
858-771-9307
Address
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Compare SPRY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
11.18 | 1.09B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-12-24 | Reiterated | Leerink Partners | Outperform |
| Jul-25-24 | Initiated | Raymond James | Outperform |
| Mar-05-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-20-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Sep-20-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jan-31-23 | Initiated | Wedbush | Outperform |
| Jan-03-23 | Initiated | William Blair | Outperform |
| Dec-13-22 | Initiated | SVB Leerink | Outperform |
View All
Ars Pharmaceuticals Inc Stock (SPRY) Latest News
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 4% After Insider Selling - MarketBeat
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock By Investing.com - Investing.com South Africa
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal - GlobeNewswire
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock - Investing.com
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock - MarketBeat
Ars Pharmaceuticals CEO sells $1.17 million in stock By Investing.com - Investing.com UK
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpStill a Buy? - MarketBeat
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
ARS Pharmaceuticals to Present at J.P. Morgan's Prestigious Healthcare Conference - StockTitan
Franklin Resources Inc. Trims Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell Alert: Justin Chakma Sells 144,605 Shares of ARS Ph - GuruFocus.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey Sells 25,000 Shares - MarketBeat
Justin Chakma Sells 27,272 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.5%What's Next? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Ars Pharmaceuticals' chief business officer sells $1.77m in stock By Investing.com - Investing.com Australia
Ars Pharmaceuticals' chief business officer sells $1.77m in stock - Investing.com India
Ars Pharmaceuticals COO Brian Dorsey sells $493,858 in stock By Investing.com - Investing.com Australia
Ars Pharmaceuticals COO Brian Dorsey sells $493,858 in stock - Investing.com
ARS Pharmaceuticals 宣布在中国、日本和澳大利亚申请批准 neffy® - GlobeNewswire Inc.
ARS Pharmaceuticals seeks Asia Pacific neffy approvals By Investing.com - Investing.com Canada
Ars Pharmaceuticals' chief business officer sells shares worth $657,625 By Investing.com - Investing.com Nigeria
Ars Pharmaceuticals' chief business officer sells shares worth $657,625 - Investing.com India
ARS Pharmaceuticals seeks Asia Pacific neffy approvals - Investing.com India
ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia - The Manila Times
ARS Pharma's Neffy Nasal Spray Seeks Approval in Asia-Pacific After Breakthrough Clinical Results - StockTitan
SPRYARS Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
NEURELIS ENTERS $208 MILLION AGREEMENT TO MONETIZE INTRAVAIL ROYALTIES - The Eastern Progress Online
Wexford Capital LP Makes New $3.60 Million Investment in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) Proactive Strategies - Stock Traders Daily
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Justin Chakma Sells 50,000 Shares - MarketBeat
Cantor Fitzgerald Analysts Lower Earnings Estimates for SPRY - MarketBeat
Ars Pharmaceuticals' chief business officer sells $2.04 million in stock By Investing.com - Investing.com Canada
Insider Sell: Justin Chakma Sells 90,000 Shares of ARS Pharmaceu - GuruFocus.com
Jacobs Levy Equity Management Inc. Buys 288,021 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell: Eric Karas Sells 10,000 Shares of ARS Pharmaceuticals Inc (SPRY) - GuruFocus.com
Ars Pharmaceuticals director Laura Shawver sells shares for $2.69 million By Investing.com - Investing.com Nigeria
Ars Pharmaceuticals chief commercial officer sells $140,423 in stock - Investing.com India
Ars Pharmaceuticals' chief business officer sells $1.2 million in stock By Investing.com - Investing.com Canada
Ars Pharmaceuticals director Laura Shawver sells shares for $2.69 million - Investing.com
Ars Pharmaceuticals' chief business officer sells $1.2 million in stock - Investing.com
ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost - The Manila Times
ARS Pharmaceuticals Launches Free Nasal Spray Allergy Program for K-12 Schools, Tackles Critical Safety Need - StockTitan
Miura Global Management LLC Takes $3.92 Million Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Neurelis Offs Neffy Stake for $208M - San Diego Business Journal
Trade Alert: Chief Business Officer & Secretary Of ARS Pharmaceuticals Justin Chakma Has Sold Stock - Simply Wall St
Connor Clark & Lunn Investment Management Ltd. Takes Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Consensus Target Price from Brokerages - MarketBeat
Insider Sell: Justin Chakma Sells 100,000 Shares of ARS Pharmace - GuruFocus.com
US Growth Stocks With High Insider Ownership For November 2024 - Simply Wall St
Ars Pharmaceuticals Inc Stock (SPRY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):